Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins.

Basic & clinical pharmacology & toxicology - 1 May 2010

Lacchini Riccardo, Silva Pamela S, Tanus-Santos Jose E

Abstract excerpt

Nitric oxide (NO) is the main endothelial-derived relaxation factor and plays a major role in cardiovascular homeostasis. This key signalling molecule is synthesised by a family of nitric oxide synthases (NOS), and the endothelial isoform (eNOS) is the most important for nitric oxide formation in the cardiovascular system. Cardiovascular drugs including statins increase eNOS expression and up-regulate NO...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atorvastatin
Share to Cardiovascular Diseases
Share to Cardiovascular System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heptanoic Acids

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Nitric Oxide

Share to Nitric Oxide Synthase Type III

Share to Pyrroles

Source

Identifiers

PMID: 20210789
DOI: 10.1111/j.1742-7843.2010.00551.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins.PMID 20210789Read ↗

Prognostic Implications of Genetics in Cardiovascular Disease.Semantic proximity Read ↗

Endothelial nitric oxide synthase gene: prospects for treatment of heart disease.Semantic proximity Read ↗

Pharmacogenetics of statins treatment: Efficacy and safetySemantic proximity Read ↗

Genetic determinants of response to statins.Semantic proximity Read ↗

Clinical and pharmacogenetic impact of endothelial nitric oxide synthase polymorphisms on cardiovascular diseasesSemantic proximity Read ↗

Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease.Semantic proximity Read ↗

When the same treatment has different response: The role of pharmacogenomics in statin therapySemantic proximity Read ↗

Endothelial nitric oxide synthase (eNOS) variants in cardiovascular disease: pharmacogenomic implications.Semantic proximity Read ↗

Association of endothelial nitric oxide synthase promoter region (T-786C) gene polymorphism with acute coronary syndrome and coronary heart disease.Semantic proximity Read ↗

Endothelial nitric oxide synthase gene polymorphisms in cardiovascular disease.Semantic proximity Read ↗

Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart DiseaseSemantic proximity Read ↗

Pharmacogenomic importance of pravastatin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.